Holen Sie sich die Stockscreener-App
2.03
12.15%
0.22
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - Defense World
Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CABA Stock News: Citigroup Lowers Price Target but Maintains Buy - GuruFocus
CABA: Guggenheim Raises Price Target for Cabaletta Bio to $25 | CABA Stock News - GuruFocus
UBS Adjusts Price Target on Cabaletta Bio to $6 From $7, Maintains Buy Rating - marketscreener.com
Cabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating - TipRanks
Cabaletta Bio (CABA) Price Target Slashed by Citi, Keeps Buy Rating | CABA Stock News - GuruFocus
Cabaletta Bio Extends Gains Premarket as FDA Meeting Fuels Expectations for Myositis BLA Submission - marketscreener.com
41,626 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by Stifel Financial Corp - Defense World
Cabaletta Bio (CABA) Expected to Announce Earnings on Wednesday - MarketBeat
Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased - Asianet Newsable
Fred Alger Management LLC Sells 1,803,170 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
CABA: Guggenheim Raises Price Target to $25, Maintains Buy Ratin - GuruFocus
CABA: Guggenheim Raises Price Target to $25, Maintains Buy Rating | CABA Stock News - GuruFocus
Guggenheim Increases Price Target for Cabaletta Bio (CABA) to $2 - GuruFocus
Cabaletta Bio (CABA) Targets 2027 for Rese-cel BLA Submission | - GuruFocus
Cabaletta Bio Inc (CABA) Reports Q1 EPS Miss at -0.64, No Revenue Recorded - GuruFocus
Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts - marketscreener.com
Cabaletta Bio, Inc. SEC 10-Q Report - TradingView
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent ... - Eagle-Tribune
Breakthrough: FDA Grants RMAT Status to Cabaletta's Myositis Therapy, Accelerating Path to 2027 BLA - Stock Titan
Barclays PLC Boosts Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio (CABA) to Release Quarterly Earnings on Wednesday - Defense World
Wells Fargo & Company MN Purchases 16,250 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
LAWSUITS FILED AGAINST CRNC, CABA and FBJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
LAWSUITS FILED AGAINST BMBL, CABA and RIVNJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
LAWSUITS FILED AGAINST CRNC, CABA and AFRMJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
LAWSUITS FILED AGAINST CLVT, CRNC and CABAJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Envestnet Asset Management Inc. Trims Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Renaissance Technologies LLC Takes Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
T. Rowe Price Investment Management Inc. Buys 400,282 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
230,161 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Purchased by Renaissance Technologies LLC - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
It would be worthwhile to take a closer look at Cabaletta Bio Inc (CABA) - uspostnews.com
Market Recap: Cabaletta Bio Inc (CABA)’s Negative Momentum, Closing at 1.25 - DWinneX
Cabaletta Bio Inc’s Banking’s 100-Day Moving Average at 2.0189: Will the Stock Break Through? - investchronicle.com
Walleye Capital LLC Reduces Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
JPMorgan Chase & Co. Cuts Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Geode Capital Management LLC Buys 16,058 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CABA’s Financial Health: Exploring Cabaletta Bio Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Is Cabaletta Bio Inc (CABA) a good investment opportunity? - uspostnews.com
American Superconductor Corp (AMSC) requires closer examination - uspostnews.com
Aehr Test Systems (AEHR) shows promising results - uspostnews.com
Wellington Management Group LLP Has $409,000 Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
William Blair Increases Earnings Estimates for Cabaletta Bio - MarketBeat
HC Wainwright Weighs in on Cabaletta Bio FY2029 Earnings - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):